Assessment of liver tumor response to therapy: Role of quantitative imaging

Fernanda D. Gonzalez-Guindalini, Marcos P F Botelho, Carla B. Harmath, Kumar Sandrasegaran, Frank H. Miller, Riad Salem, Vahid Yaghmai

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Quantitative imaging is the analysis of retrieved numeric data from images with the goal of reducing subjective assessment. It is an increasingly important radiologic tool to assess treatment response in oncology patients. Quantification of response to therapy depends on the tumor type and method of treatment. Anatomic imaging biomarkers that quantify liver tumor response to cytotoxic therapy are based on temporal change in the size of the tumors. Anatomic biomarkers have been incorporated into the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) versions 1.0 and 1.1. However, the development of novel therapies with different mechanisms of action, such as antiangiogenesis or radioembolization, has required new methods for measuring response to therapy. This need has led to development of tumor- or therapy-specific guidelines such as the Modified CT Response Evaluation (Choi) Criteria for gastrointestinal stromal tumors, the European Association for Study of the Liver (EASL) criteria, and modified RECIST for hepatocellular carcinoma, among many others. The authors review the current quantification criteria used in the evaluation of treatment response in liver tumors, summarizing their indications, advantages, and disadvantages, and discuss future directions with newer methods that have the potential for assessment of treatment response. Knowledge of these quantitative methods is important to facilitate pivotal communication between oncologists and radiologists about cancer treatment, with benefit ultimately accruing to the patient.

Original languageEnglish
Pages (from-to)1781-1800
Number of pages20
JournalRadiographics
Volume33
Issue number6
DOIs
StatePublished - Oct 2013

Fingerprint

Liver
Neoplasms
Therapeutics
Biomarkers
Gastrointestinal Stromal Tumors
Hepatocellular Carcinoma
Communication
Guidelines
Response Evaluation Criteria in Solid Tumors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Gonzalez-Guindalini, F. D., Botelho, M. P. F., Harmath, C. B., Sandrasegaran, K., Miller, F. H., Salem, R., & Yaghmai, V. (2013). Assessment of liver tumor response to therapy: Role of quantitative imaging. Radiographics, 33(6), 1781-1800. https://doi.org/10.1148/rg.336135511

Assessment of liver tumor response to therapy : Role of quantitative imaging. / Gonzalez-Guindalini, Fernanda D.; Botelho, Marcos P F; Harmath, Carla B.; Sandrasegaran, Kumar; Miller, Frank H.; Salem, Riad; Yaghmai, Vahid.

In: Radiographics, Vol. 33, No. 6, 10.2013, p. 1781-1800.

Research output: Contribution to journalArticle

Gonzalez-Guindalini, FD, Botelho, MPF, Harmath, CB, Sandrasegaran, K, Miller, FH, Salem, R & Yaghmai, V 2013, 'Assessment of liver tumor response to therapy: Role of quantitative imaging', Radiographics, vol. 33, no. 6, pp. 1781-1800. https://doi.org/10.1148/rg.336135511
Gonzalez-Guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R et al. Assessment of liver tumor response to therapy: Role of quantitative imaging. Radiographics. 2013 Oct;33(6):1781-1800. https://doi.org/10.1148/rg.336135511
Gonzalez-Guindalini, Fernanda D. ; Botelho, Marcos P F ; Harmath, Carla B. ; Sandrasegaran, Kumar ; Miller, Frank H. ; Salem, Riad ; Yaghmai, Vahid. / Assessment of liver tumor response to therapy : Role of quantitative imaging. In: Radiographics. 2013 ; Vol. 33, No. 6. pp. 1781-1800.
@article{f215c0ab8a184667b6bda73dcb68e7ec,
title = "Assessment of liver tumor response to therapy: Role of quantitative imaging",
abstract = "Quantitative imaging is the analysis of retrieved numeric data from images with the goal of reducing subjective assessment. It is an increasingly important radiologic tool to assess treatment response in oncology patients. Quantification of response to therapy depends on the tumor type and method of treatment. Anatomic imaging biomarkers that quantify liver tumor response to cytotoxic therapy are based on temporal change in the size of the tumors. Anatomic biomarkers have been incorporated into the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) versions 1.0 and 1.1. However, the development of novel therapies with different mechanisms of action, such as antiangiogenesis or radioembolization, has required new methods for measuring response to therapy. This need has led to development of tumor- or therapy-specific guidelines such as the Modified CT Response Evaluation (Choi) Criteria for gastrointestinal stromal tumors, the European Association for Study of the Liver (EASL) criteria, and modified RECIST for hepatocellular carcinoma, among many others. The authors review the current quantification criteria used in the evaluation of treatment response in liver tumors, summarizing their indications, advantages, and disadvantages, and discuss future directions with newer methods that have the potential for assessment of treatment response. Knowledge of these quantitative methods is important to facilitate pivotal communication between oncologists and radiologists about cancer treatment, with benefit ultimately accruing to the patient.",
author = "Gonzalez-Guindalini, {Fernanda D.} and Botelho, {Marcos P F} and Harmath, {Carla B.} and Kumar Sandrasegaran and Miller, {Frank H.} and Riad Salem and Vahid Yaghmai",
year = "2013",
month = "10",
doi = "10.1148/rg.336135511",
language = "English",
volume = "33",
pages = "1781--1800",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "6",

}

TY - JOUR

T1 - Assessment of liver tumor response to therapy

T2 - Role of quantitative imaging

AU - Gonzalez-Guindalini, Fernanda D.

AU - Botelho, Marcos P F

AU - Harmath, Carla B.

AU - Sandrasegaran, Kumar

AU - Miller, Frank H.

AU - Salem, Riad

AU - Yaghmai, Vahid

PY - 2013/10

Y1 - 2013/10

N2 - Quantitative imaging is the analysis of retrieved numeric data from images with the goal of reducing subjective assessment. It is an increasingly important radiologic tool to assess treatment response in oncology patients. Quantification of response to therapy depends on the tumor type and method of treatment. Anatomic imaging biomarkers that quantify liver tumor response to cytotoxic therapy are based on temporal change in the size of the tumors. Anatomic biomarkers have been incorporated into the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) versions 1.0 and 1.1. However, the development of novel therapies with different mechanisms of action, such as antiangiogenesis or radioembolization, has required new methods for measuring response to therapy. This need has led to development of tumor- or therapy-specific guidelines such as the Modified CT Response Evaluation (Choi) Criteria for gastrointestinal stromal tumors, the European Association for Study of the Liver (EASL) criteria, and modified RECIST for hepatocellular carcinoma, among many others. The authors review the current quantification criteria used in the evaluation of treatment response in liver tumors, summarizing their indications, advantages, and disadvantages, and discuss future directions with newer methods that have the potential for assessment of treatment response. Knowledge of these quantitative methods is important to facilitate pivotal communication between oncologists and radiologists about cancer treatment, with benefit ultimately accruing to the patient.

AB - Quantitative imaging is the analysis of retrieved numeric data from images with the goal of reducing subjective assessment. It is an increasingly important radiologic tool to assess treatment response in oncology patients. Quantification of response to therapy depends on the tumor type and method of treatment. Anatomic imaging biomarkers that quantify liver tumor response to cytotoxic therapy are based on temporal change in the size of the tumors. Anatomic biomarkers have been incorporated into the World Health Organization criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) versions 1.0 and 1.1. However, the development of novel therapies with different mechanisms of action, such as antiangiogenesis or radioembolization, has required new methods for measuring response to therapy. This need has led to development of tumor- or therapy-specific guidelines such as the Modified CT Response Evaluation (Choi) Criteria for gastrointestinal stromal tumors, the European Association for Study of the Liver (EASL) criteria, and modified RECIST for hepatocellular carcinoma, among many others. The authors review the current quantification criteria used in the evaluation of treatment response in liver tumors, summarizing their indications, advantages, and disadvantages, and discuss future directions with newer methods that have the potential for assessment of treatment response. Knowledge of these quantitative methods is important to facilitate pivotal communication between oncologists and radiologists about cancer treatment, with benefit ultimately accruing to the patient.

UR - http://www.scopus.com/inward/record.url?scp=84885346753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885346753&partnerID=8YFLogxK

U2 - 10.1148/rg.336135511

DO - 10.1148/rg.336135511

M3 - Article

C2 - 24108562

AN - SCOPUS:84885346753

VL - 33

SP - 1781

EP - 1800

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 6

ER -